LIPO Lipella Pharmaceuticals Inc.
USHealthcareAs of 2026-07-08 16:00
Why LIPO matters now
Lipella Pharmaceuticals Inc. (LIPO) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.07 with -9.60% on the session and $300.4K in market capitalization; recent performance reads 1-month -52.86% and YTD -55.56%.
The latest financial table shown here is Q3 2025, with revenue of $0.00, net income of $-1.3M, and EPS of $-0.28. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -638848.4%.
Additional event context on this page matters because analyst consensus is Buy with a median target of $2.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.24
P/S
2.13
EV/EBITDA
0.23
DCF Value
$-4.99
FCF Yield
-638848.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1954.7%
Operating Margin
-3115.2%
Net Margin
-3069.0%
ROE
-208.4%
ROA
-226.8%
ROIC
-308.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0.00 | $-1.3M | $-0.28 |
| Q2 2025 | $0.00 | $-1.3M | $-0.31 |
| Q1 2025 | $0.00 | $-1.3M | $-0.64 |
| Q4 2024 | $173.7K | $-1.4M | $-1.37 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$2.00
Target (Median)
$2.00
Target Range
$2.00 - $2.00
Related Stocks
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.50
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.